Coherus Oncology, Inc. (NASDAQ:CHRS – Get Free Report) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.67 and traded as high as $1.71. Coherus Oncology shares last traded at $1.67, with a volume of 1,525,559 shares changing hands.
Wall Street Analyst Weigh In
CHRS has been the subject of several research reports. Wall Street Zen raised Coherus Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Weiss Ratings raised Coherus Oncology from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 13th. Finally, Guggenheim initiated coverage on Coherus Oncology in a research report on Monday, May 11th. They issued a “buy” rating and a $12.00 price objective on the stock. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.67.
View Our Latest Research Report on CHRS
Coherus Oncology Stock Performance
Coherus Oncology (NASDAQ:CHRS – Get Free Report) last issued its quarterly earnings results on Monday, May 11th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.01. The firm had revenue of $12.31 million for the quarter, compared to analyst estimates of $14.22 million. Coherus Oncology had a negative return on equity of 198.90% and a net margin of 397.30%. Research analysts forecast that Coherus Oncology, Inc. will post -0.86 earnings per share for the current year.
Institutional Investors Weigh In On Coherus Oncology
Institutional investors have recently bought and sold shares of the stock. Acadian Asset Management LLC increased its position in Coherus Oncology by 52,980.1% during the first quarter. Acadian Asset Management LLC now owns 196,927 shares of the biotechnology company’s stock worth $158,000 after purchasing an additional 196,556 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Coherus Oncology by 0.8% in the 2nd quarter. Geode Capital Management LLC now owns 2,676,476 shares of the biotechnology company’s stock valued at $1,958,000 after purchasing an additional 20,976 shares during the last quarter. XTX Topco Ltd grew its stake in shares of Coherus Oncology by 65.3% during the 2nd quarter. XTX Topco Ltd now owns 91,739 shares of the biotechnology company’s stock valued at $67,000 after buying an additional 36,257 shares during the period. Invesco Ltd. increased its holdings in shares of Coherus Oncology by 11.5% during the 2nd quarter. Invesco Ltd. now owns 208,271 shares of the biotechnology company’s stock worth $152,000 after buying an additional 21,550 shares during the last quarter. Finally, Jane Street Group LLC acquired a new stake in shares of Coherus Oncology during the 2nd quarter worth $46,000. 72.82% of the stock is currently owned by hedge funds and other institutional investors.
About Coherus Oncology
Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.
The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.
Read More
- Five stocks we like better than Coherus Oncology
- Apple and Broadcom Forge a Decade-Long Silicon Fortress
- SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
- The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
- Palantir’s CEO Just Called Out OpenAI and Anthropic
Receive News & Ratings for Coherus Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
